Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Single Subcutaneous MT203 in Healthy Japanese and Caucasian Males
jRCT2080222648Phase 1
- Sponsor
- Takeda
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of namilumab (4 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of single subcutaneous MT203 and Pharmacokinetics of MT203.
02
Drugs
namilumab
Beyond the preview
Go deeper on jRCT2080222648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222648.